Real-World Natalizumab Biosimilar Switch Reduced Treatment Satisfaction Despite Stable Outcomes

July 20, 2026

Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, likely due to a nocebo effect.

Romosozumab Biosimilar Matches Reference in Functional Testing Despite Disulfide Differences

July 16, 2026

FDA Accepts Sandoz Generic Tirzepatide Applications Amid Biosimilar Development Gap

July 13, 2026

Anti-VEGF Biosimilars Match Reference Drug in Indian Retinal Disease Care

July 09, 2026

Rituximab Biosimilar Reached 75% Remission, Matched Innovator in Membranous Nephropathy

July 08, 2026

Featured Content

How Streamlining Development Can Save the US Biosimilar Industry

AAM White Paper Breaks Down Drug Shortage Crisis: Causes and Solutions

several filled syringes in different sizes and colors

Samsung Bioepis Report Proves Lower Biosimilar Prices Correlate With Greater Market Share

Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility

Biosimilar ABP 654 Maintains Efficacy, Safety After Repeated Switching From Ustekinumab

July 7th 2026

By Skylar Jeremias

Article

Trial data show switching between ABP 654 and reference ustekinumab maintains similar psoriasis control, safety, and immunogenicity, supporting FDA interchangeability confidence.

Biosimilar Denosumab Matches Reference Drug for Bone Density in Chinese Women

July 6th 2026

By Skylar Jeremias

Article

Phase 3 data show denosumab biosimilar KN012 matches Prolia for BMD gains and safety, potentially expanding affordable osteoporosis care.

Biosimilar Makers Push Forward on Regulatory and Commercial Fronts

July 2nd 2026

By Skylar Jeremias

Article

FDA expands Tofidence uses, Teva launches Eylea biosimilar in Europe, and Alvotech’s Entyvio rival enters FDA review—boosting access.

Positioning Biosimilar Ustekinumab Early Reduces Burden on Spain's National Health System

June 26th 2026

By Skylar Jeremias

Article

Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe.

Global Biosimilar Rules Diverge Across WHO Regions, Limiting Patient Access

June 24th 2026

By Skylar Jeremias

Article

Global review reveals uneven biosimilar rules on waivers, interchangeability, and safety tracking—barriers to cheaper biologics and approvals.

Low Biosimilar Awareness in MS Patients Points to Critical Gap in Nurse-Led Education

June 18th 2026

By Skylar Jeremias

Article

Italian study finds most MS patients start biosimilars unaware, exposing education gaps and highlighting MS nurses as key to boosting trust and uptake.

Biosimilar Expansion, Lower Costs Drive Shift in RA Treatment Guidelines

June 18th 2026

By Skylar Jeremias

Article

New EULAR guidelines speed RA treatment switches as rheumatoid arthritis biosimilars and cost savings push earlier biologics use.

FDA Approves Ranibizumab-hkdz as First Interchangeable, Available in Both Vials and Prefilled Syringes

June 17th 2026

By Cyrus Karkaria, PhD

Article

The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.

Biosimilar Switching Maintained Disease Control in People With Ankylosing Spondylitis

June 16th 2026

By Skylar Jeremias

Article

Evidence shows biosimilars switching in ankylosing spondylitis maintains disease control with biologics, cuts costs, and highlights nocebo risks.

FDA Approves First Biosimilars Interchangeable With Simponi/Simponi Aria

June 10th 2026

By MHE Staff

Article

Immgolis and Immgolis Intri have the same indications as Simponi and Simponi Aria, treating patients with rheumatoid arthritis and ulcerative colitis. The biosimilars will be available in the fourth quarter of this year.